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The last decade has seen the advent of a variety of novel
biologic agents, which are now used widely across a
range of the inflammatory rheumatic diseases. Normally
introduced after the trial and failure of conventional dis-
ease modifying anti-rheumatic drugs (DMARDs) the bio-
logic class of medicines has been a revolutionary in terms
of the scope and depth of response now sought in treating
rheumatic diseases. Those best characterized are TNFi,
IL-6Ri, rituximab and abatacept, all of which bring about
improvement in clinical signs and symptoms, and var-
iously mitigate articular destruction and improve function.
Application of drugs developed for other indications
but now being tested in rheumatic diseases has raised
interest in the possible value of agents such as ustekinumab
(inhibiting IL-12/23), and several antibodies that block
the biology of IL-17. The latter appear to exhibit especial
benefits in the spondylo arthropathies and psoriatic
variants of inflammatory arthropathy. Other studies target-
ing GM-CSF receptor have similarly shown benefit in early
studies in rheumatoid arthritis. The long promised possi-
bility that chemokines and their receptors would deliver
benefit now has some tentative evidence for benefit. In this
presentation I shall describe the successes and failures
of recent biologic therapeutic studies in the rheumatic
disease, and wider inflammatory arena, and from this draw
inferences as to new emerging understanding of the
molecular taxonomy of the inflammatory diseases.
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